NASDAQ:HSCS Heart Test Laboratories (HSCS) Stock Price, News & Analysis $4.58 +0.83 (+22.13%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.80▼$4.6250-Day Range$3.66▼$6.8152-Week Range$3.40▼$98.00Volume295,158 shsAverage Volume53,285 shsMarket Capitalization$3.02 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Heart Test Laboratories alerts: Email Address Ad Crypto 101 MediaNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…Check out the new "Crypto Bull Run Millionaire Blueprint" now! About Heart Test Laboratories Stock (NASDAQ:HSCS)Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.Read More HSCS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HSCS Stock News HeadlinesJuly 26 at 10:43 PM | finance.yahoo.comInnovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway EfficiencyJuly 26 at 9:00 AM | globenewswire.comInnovation Value Institute Analysis Demonstrates HeartSciences' MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway EfficiencyJuly 27, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…July 25 at 8:30 AM | globenewswire.comHeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform HealthcareJuly 11, 2024 | globenewswire.comHeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart DysfunctionJune 4, 2024 | globenewswire.comHeartSciences Regains Compliance with Nasdaq Listing RequirementsMay 20, 2024 | globenewswire.comHeartSciences Announces Further Internationalization of its AI-ECG Patent PortfolioMay 17, 2024 | msn.comHeart Test conducts 1-for-100 reverse stock splitJuly 27, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…April 30, 2024 | msn.comResearchers develop genetic test for early detection of high cardiovascular riskApril 29, 2024 | abcnews.go.comFDA brings lab tests under federal oversight in bid to improve accuracy and safetyApril 24, 2024 | globenewswire.comHeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECGApril 13, 2024 | msn.comRoche Diagnostics India launches heart failure test for diabetics in IndiaApril 4, 2024 | msn.comEarly coronary disease, impaired heart function found in asymptomatic people with HIVApril 4, 2024 | msn.comThe Importance of Regular Lipid Profile Testing For Cardiovascular WellnessApril 2, 2024 | globenewswire.comHeartSciences to Present at the LD Micro Invitational XIV ConferenceMarch 26, 2024 | globenewswire.comHeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative PatientsMarch 15, 2024 | finanznachrichten.deHeart Test Laboratories, Inc.: HeartSciences Reports Third Quarter Fiscal 2024 Financial ResultsSee More Headlines Receive HSCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heart Test Laboratories and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings12/14/2023Today7/26/2024Next Earnings (Estimated)7/30/2024Fiscal Year End4/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical appliances & supplies Sub-IndustryN/A Current SymbolNASDAQ:HSCS CUSIPN/A CIK1468492 Webheartsciences.com Phone682-237-7781FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($48.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,350,000.00 Net MarginsN/A Pretax Margin-33,636.84% Return on Equity-381.92% Return on Assets-134.17% Debt Debt-to-Equity RatioN/A Current Ratio5.09 Quick Ratio4.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.37 per share Price / Book1.93Miscellaneous Outstanding Shares660,000Free Float638,000Market Cap$3.02 million OptionableNot Optionable Beta3.12 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Andrew Simpson (Age 54)CEO, President & Chairman of the Board of Directors Comp: $264.14kMs. Danielle Watson (Age 41)CFO & Treasurer Comp: $188.75kMr. Mark T. Hilz (Age 65)COO, Secretary & Director Comp: $263.61kKey CompetitorsPredictive OncologyNASDAQ:POAINanoVibronixNASDAQ:NAOVBone BiologicsNASDAQ:BBLGLogicMarkNASDAQ:LGMKSientraNASDAQ:SIENQView All Competitors HSCS Stock Analysis - Frequently Asked Questions How have HSCS shares performed this year? Heart Test Laboratories' stock was trading at $17.10 at the beginning of 2024. Since then, HSCS stock has decreased by 73.2% and is now trading at $4.58. View the best growth stocks for 2024 here. How were Heart Test Laboratories' earnings last quarter? Heart Test Laboratories, Inc. (NASDAQ:HSCS) posted its quarterly earnings data on Thursday, December, 14th. The company reported ($16.00) earnings per share for the quarter, missing analysts' consensus estimates of ($12.00) by $4.00. When did Heart Test Laboratories' stock split? Shares of Heart Test Laboratories reverse split on the morning of Friday, May 17th 2024. The 1-100 reverse split was announced on Friday, May 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did Heart Test Laboratories IPO? Heart Test Laboratories (HSCS) raised $9 million in an initial public offering on Wednesday, June 15th 2022. The company issued 1,800,000 shares at a price of $4.50-$5.50 per share. The Benchmark Company served as the underwriter for the IPO. How do I buy shares of Heart Test Laboratories? Shares of HSCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HSCS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heart Test Laboratories, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heart Test Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.